Regulatory, Ethical and Patient Engagement Considerations for Plain Language Summaries_hero image

The European Medicines Agency (EMA) and the US Food and Drug Administration differ on their approach to plain language summaries (PLS) of clinical trials.

Related resources

Trial Summaries-Improving Patient-Centric Communications resource-card-thumbnail
JUL 01, 2023
White paper
Regulatory & Compliance

Trial Summaries Improving Patient-Centric Communications

The Pharma R&D Annual Review 2023 Supplement looks at new active substances (NASs), drugs launched onto the market for the first time, during 2022

Hands typing on a laptop device.
DEC 17, 2021
Article
Regulatory & Compliance

Considerations for Creating Plain Language Summaries

Writing plain language summaries can be a huge undertaking, especially if translations or a patient review panel are required. See what PLS should include.